Form 4: Twist Bioscience Executive Sells Shares to Cover Tax Obligations

Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp., sold 257 shares of common stock for tax withholding purposes related to Restricted Stock Unit vesting.

Summary

• Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp. (TWST), reported a transaction on June 6, 2025.
• The transaction involved the sale of 257 shares of common stock at a price of $31.75 per share.
• This sale was a 'sell to cover' transaction, mandated by the issuer's equity incentive plans to satisfy tax withholding obligations upon the vesting of Restricted Stock Units.
• The sale was not a discretionary trade by Mr. Cho.
• Following this transaction, Mr. Cho beneficially owns 105,061 shares of common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a non-discretionary 'sell to cover' for tax purposes, which is a routine event and does not reflect a positive or negative discretionary action by the insider.

Positives

• The sale was non-discretionary, indicating it was not a reflection of the executive's sentiment regarding the company's future performance.
• The transaction is a routine part of equity compensation plans, demonstrating the vesting of Restricted Stock Units for the executive.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sale represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
• These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

This specific Form 4 filing, detailing a non-discretionary 'sell to cover' transaction, is a routine event in the biotechnology and life sciences industry, where equity compensation, including Restricted Stock Units, is a common component of executive remuneration. Such transactions are typically not indicative of broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The sale of 257 shares is a very small amount relative to the company's total outstanding shares and is a non-discretionary transaction, thus having a negligible direct impact on existing shareholders.
• Employees: The transaction highlights the standard process for equity compensation and tax obligations for executives, which is common across many companies.

Key Dates

Keywords

Twist Bioscience, TWST, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Equity Compensation, Dennis Cho